Meeting
2016 ASCO Annual Meeting
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
Authors
Scott Joseph Antonia
Moffitt Cancer Center, Tampa, FL
Scott Joseph Antonia , Sang-We Kim , Alexander I. Spira , Myung-Ju Ahn , Sai-Hong Ignatius Ou , Neda Stjepanovic , Angela Fasolo , Dirk Jäger , Patrick Alexander Ott , Zev A. Wainberg , Heather A. Wakelee , Jonathan Wade Goldman , John Kurland , Marlon C. Rebelatto , Wenliang Yao , Ashok Kumar Gupta , John A. Blake-Haskins , Neil Howard Segal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01693562
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9029)
DOI
10.1200/JCO.2016.34.15_suppl.9029
Abstract #
9029
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.
First Author: Masayuki Shirasawa
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc).
First Author: Ari M. Vanderwalde